Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veverimer in Adults With CKD and Metabolic Acidosis
NCT07355062Phase 3Recruiting
- Sponsor
- Renibus Therapeutics
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of veverimer in chronic kidney disease (CKD), metabolic acidosis, sponsored by Renibus Therapeutics. Started Jan 2026; status: recruiting.
02
Drugs
veverimer
03
Conditions
chronic kidney disease (CKD)metabolic acidosis
Beyond the preview
Go deeper on NCT07355062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07355062.